608 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors

• DOI: 10.1016/s0959-8049(12)72405-x
• Publication Date: 2012-11-06T17:02:37Z
• Authors: A. Naing; M. Mita; P. Komarnitsky; A. Milner; O. von Richter; J. Ogden; S. Piha-Paul; S. Fu; E. Asatiani; R. Kurzrock
• Keywords: 03 medical and health sciences; 0302 clinical medicine